Morocco vs Yemen: Average cost of multi drug-resistant tuberculosis treatment
Morocco
2,000 constant 2022 US$
in 2024
Yemen
2,510 constant 2022 US$
in 2024
Morocco rank
22nd
Yemen rank
20th
Average cost of multi drug-resistant tuberculosis treatment over time
- Morocco
- Yemen
How they compare
Yemen currently reports 2,510 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco, a difference of 510 constant 2022 US$.
That makes Yemen's figure about 1.3 times Morocco's.
The two have swapped places 2 times across 7 shared years of data; in 2017 it was Yemen ahead.
Morocco ranks 22nd and Yemen ranks 20th of 92 countries.
Yemen has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Morocco | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,127 constant 2022 US$ | 2,720 constant 2022 US$ | 593.33 constant 2022 US$ | Yemen |
| 2020s | 1,704 constant 2022 US$ | 3,052 constant 2022 US$ | 1,349 constant 2022 US$ | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Morocco or Yemen?
- Yemen, at 2,510 constant 2022 US$ against 2,000 constant 2022 US$ in Morocco as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Morocco and Yemen?
- 510 constant 2022 US$, with Yemen ahead.
- How many years of comparable data are there for Morocco and Yemen?
- 7 years are reported by both, from 2017 to 2024.
- How do Morocco and Yemen rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Morocco ranks 22nd and Yemen ranks 20th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.